Efficacy of Pregabalin, Solifenacin, or Combination Therapy for Ureteral Stent Related Symptoms: A Systematic Review and Meta-Analysis

Nicholas Andrian Singgih; Jacinda Risha Oktaviani; William  Adipurnama; Cecilia Noviyanti  Salim; Kevin Tandarto; Athaya Febriantyo  Purnomo; Egi Edward  Manuputty

doi:10.33192/smj.v75i12.265648

Authors

Nicholas Andrian Singgih Department of Urology, Primaya Hospital PGI Cikini, Jakarta, Indonesia
Jacinda Risha Oktaviani Department of Urology, Primaya Hospital PGI Cikini, Jakarta, Indonesia
William Adipurnama Department of Urology, Primaya Hospital PGI Cikini, Jakarta, Indonesia
Cecilia Noviyanti Salim Department of Urology, Primaya Hospital PGI Cikini, Jakarta, Indonesia
Kevin Tandarto Department of Internal Medicine, University of Diponegoro, Semarang, Indonesia
Athaya Febriantyo Purnomo Department of Urology, Faculty of Medicine, Universitas Brawijaya, Saiful Anwar General Hospital, Malang, Indonesia / Department of Oncology, University of Oxford, Oxford, United Kingdom
Egi Edward Manuputty Department of Urology, Primaya Hospital PGI Cikini, Jakarta, Indonesia

DOI:

https://doi.org/10.33192/smj.v75i12.265648

Keywords:

Double-J ureteral stent, lower urinary tract symptoms, pregabalin, solifenacin, ureteral Stent related symptoms

Abstract

Objective: The Double-J (DJ) ureteral stent is essential in urology but can lead to Ureteral Stent-Related Symptoms (USRS), prompting research into various therapies to enhance patient comfort. The purpose of this study is to assess the efficacy of pregabalin, solifenacin, or combined therapy on ureteral stent-related symptoms.

Materials and Methods: We conducted thorough searches in four databases, which included PubMed, Cochrane, EBSCO, and ProQuest. PRISMA Guideline 2020 was applied in this study. The risk of bias was assessed using Newcastle-Ottawa Scale and Cochrane Risk of Bias 2.0.

Results: Ten studies consisting of 1477 participants were included in this study. Solifenacin monotherapy could significantly decrease total USSQ (mean difference (MD) -16.62; p=0.001), urinary symptoms (MD -9.16; p=0.002), and sexual matters (MD -0.81; p=0.002). Pregabalin monotherapy could significantly decrease pain (MD -7.29; p<0.00001). Compared to solifenacin monotherapy, combination therapy of pregabalin and solifenacin could significantly decrease total USSQ (MD -12.40; p <0.0001), urinary symptoms (MD -1.88; p=0.007), pain (MD -6.82; p<0.00001), sexual matters (MD -0.77; p <0.00001), and additional problems (MD -1.51; p=0.0007).

Conclusion: Combination therapy of pregabalin and solifenacin had the best advantages in lowering USRS, especially urinary symptoms, pain, sexual matters, and some other additional problems.

References

De Grazia A, Somani BK, Soria F, Carugo D, Mosayyebi A. Latest advancements in ureteral stent technology. Transl Androl Urol. 2019;8(S4):S436-41.

Yavuz A, Kilinc MF, Aydin M, Ofluoglu Y, Bayar G. Does tamsulosin or mirabegron improve ureteral stent-related symptoms? A prospective placebo-controlled study. Low Urin Tract Symptoms. 2021;13(1):17-21.

Ragab M, Soliman MG, Tawfik A, Abdel Raheem A, El-Tatawy H, Abo Farha M, et al. The role of pregabalin in relieving ureteral stent-related symptoms: a randomized controlled clinical trial. Int Urol Nephrol. 2017;49(6):961-6.

Pansaksiri T, Noppakulsatid P. Efficacy evaluation of smartphone-based Stent tracking application in follow-up patients with ureteral stents: A prospective study. Siriraj Med J. 2023;75(6):466-72 .

Joshi HB, Newns N, Stainthorpe A, MacDONAGH RP, Keeley FX, Timoney AG. Ureteral Stent symptom questionnaire: Development and validation of a multidimensional quality of life measure. J Urol. 2003;169(3):1060-4.

Ansari MS, Bharti A, Kumar R, Ranjan P, Srivastava A, Kapoor R. Gabapentin: A novel drug as add-on therapy in cases of refractory overactive bladder in children. J Pediatr Urol. 2013;9(1):17-22.

Ho C-H, Chang T-C, Lin H-H, Liu S-P, Huang K-H, Yu H-J. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms. J Formos Med Assoc. 2010;109(10):702-8.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.

Adil Mohammed A, Goerge Ghazala S, Al-Ibraheem NP. Effect of two different doses of solifenacin succinate therapy (5 mg, 10 mg) for the treatment of ureteral stent (Double J) related symptoms in comparison to placebo. Tren Med. 2018;18(6).

Abdelaziz AS, Salama NM, Ghoneem AM. Mirabegron vs. solifenacin in control of endoscopically inserted ureteral stent-related symptoms. World J Urol. 2022;40(8):2113-9.

Dellis AE, Papatsoris AG, Keeley FX Jr, Bamias A, Deliveliotis C, Skolarikos AA. Tamsulosin, solifenacin, and their combination for the treatment of Stent-related symptoms: A randomized controlled study. J Endourol. 2017;31(1):100-9.

Lee Y-J, Huang K-H, Yang H-J, Chang H-C, Chen J, Yang T-K. Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy. Urolithiasis. 2013;41(3):247-52.

Falahatkar S, Beigzadeh M, Mokhtari G, Esmaeili S, Kazemnezhad E, Amin A, et al. The effects of pregabalin, solifenacin and their combination therapy on ureteral double-J stent-related symptoms: A randomized controlled clinical trial. Int Braz J Urol. 2021;47(3):596-609.

Abdelhamid MH, Zayed AS, Ghoneima WE, Elmarakbi AA, El Sheemy MS, Aref A, et al. Randomized, double-blind, placebo-controlled trial to compare solifenacin versus trospium chloride in the relief of double-J stent-related symptoms. World J Urol. 2017;35(8):1261-8.

EL-Nahas AR, Tharwat M, Elsaadany M, Mosbah A, Gaballah MA. A randomized controlled trial comparing alpha blocker (tamsulosin) and anticholinergic (solifenacin) in treatment of ureteral stent-related symptoms. World J Urol. 2016;34(7):963-8.

Park J, Yoo C, Han DH, Shin DW. A critical assessment of the effects of tamsulosin and solifenacin as monotherapies and as a combination therapy for the treatment of ureteral stent-related symptoms: a 2 × 2 factorial randomized trial. World J Urol. 2015;33(11):1833-40.

Liu Q, Liao B, Zhang R, Jin T, Zhou L, Luo D, et al. Combination therapy only shows short-term superiority over monotherapy on ureteral stent-related symptoms – outcome from a randomized controlled trial. BMC Urol. 2016;16(1):66.

Bhattar R, Tomar V, Yadav SS, Dhakad DS. Comparison of safety and efficacy of silodosin, solifenacin, tadalafil and their combinations in the treatment of double-J stent- related lower urinary system symptoms: A prospective randomized trial. Turk J Urol. 2018;44(3):228-38.

Wang J, Zhang X, Zhang T, Mu J, Bai B, Lei Y. The role of solifenacin, as monotherapy or combination with tamsulosin in ureteral stent-related symptoms: a systematic review and meta-analysis. World J Urol. 2017;35(11):1669-80.

Koprowski C, Kim C, Modi PK, Elsamra SE. Ureteral Stent-associated pain: A review. J Endourol. 2016;30(7):744-53.

Gadzhiev N, Gorelov D, Malkhasyan V, Akopyan G, Harchelava R, Mazurenko D, et al. Comparison of silicone versus polyurethane ureteral stents: a prospective controlled study. BMC Urol. 2020;20(1):10.

Jayaram K, Choppa S, Gurajala I, Kar P, Durga P, Devraj R, et al. Effect of pregabalin on postoperative pain and instrumentation-induced dysuria in patients undergoing percutaneous nephrolithotomy: A prospective randomized, double-blinded placebo-controlled study. J Anaesthesiol Clin Pharmacol. 2022;38(4):566.

Wang J, Zhou Z, Cui Y, Li Y, Yuan H, Gao Z, et al. Meta‐analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. Neurourol Urodyn. 2019;38(1):22-30.

Fischer KM, Louie M, Mucksavage P. Ureteral stent discomfort and its management. Curr Urol Rep. 2018;19(8):64.

Evrüke İM, Taş İS. The effect of solifenacin treatment for urge urinary incontinence on sexual function in premenopausal and postmenopausal women: a prospective observational study. Cukurova Med J. 2023;48(1):200-7.

Kosilov K, Kuzina I, Kuznetsov V, Gainullina Y, Kosilova L, Karashchuk E, et al. The risk of sexual dysfunction and effectiveness of treatment of benign prostatic hyperplasia with severe lower urinary tract dysfunction with combination of dutasteride and solifenacin. J Sex Med. 2018;15(11):1579-90.

Tang Q-L, Zhou S, Liu Y-Q, Wu J, Tao R-Z. Efficacy and safety of combination of mirabegron and solifenacin in patients with double-J stent related overactive bladder: a prospective study. Sci Rep. 2022;12(1):18844.

Sahin A, Yildirim C, Yuksel OH, Ürkmez A. Treatment of ureteral catheter related symptoms; mirabegron versus tamsulosin/solifenacin combination: A randomized controlled trial. Arch Esp Urol. 2020;73(1):54-9.

Verma V, Singh N, Singh Jaggi A. Pregabalin in Neuropathic Pain: Evidences and Possible Mechanisms. Curr Neuropharmacol. 2014;12(1):44-56.

Chaisewikul R, Saejong R, Tongsai S, Thamlikitkul V. Comparative effectiveness and safety of original gabapentin and generic gabapentin in treating patients with neuropathic pain at Siriraj hospital, Bangkok, Thailand. Siriraj Med J. 2012;64(6):172-77

Chotikawanich E, Leewansangtong S, Liangkobkit K, Nualyong C, Srinualnad S, Chaiyaprasithi B, et al. The feasibility and outcomes of retrograde intrarenal surgery to treat staghorn renal calculi. Siriraj Med J. 2023;75(5):362-8.

Rosen G, Hargis P, Lough C, Kahveci A, Moss A, Golzy M, et al. Mp10-20 single dose preoperative pregabalin in ureteroscopy – results of a randomized controlled trial. J Urol. 2023;209(Suppl 4):e122.

Agarwal MM, Elsi Sy M. Gabapentenoids in pain management in urological chronic pelvic pain syndrome: Gabapentin or pregabalin? Neurourol Urodyn. 2017;36(8):2028-33.

Park K-H, Chung N-S, Chung H-W, Kim TY, Lee H-D. Pregabalin as an effective treatment for acute postoperative pain following spinal surgery without major side effects: protocol for a prospective, randomized controlled, double-blinded trial. Trials. 2023;24(1):422.

Meaadi J, Obara I, Eldabe S, Nazar H. The safety and efficacy of gabapentinoids in the management of neuropathic pain: a systematic review with meta-analysis of randomised controlled trials. Int J Clin Pharm. 2023;45(3):556-65.

Mathias S, Wiseman O. Silicone vs. Polyurethane Stent: The final countdown. J Clin Med. 2022;11(10):2746.

Ehsanullah SA, Bruce A, Juman C, Krishan A, Krishan A, Higginbottom J, et al. Stent diameter and stent-related symptoms, does size matter? A systematic review and meta-analysis. Urol Ann. 2022;14(4):295-302.

Bao X, Sun F, Yao H, Wang D, Liu H, Tang G, et al. Distal end of Double-J ureteral stent position on ureteral stent-related symptoms: A systematic review and meta-analysis. Front Surg. 2022;9:990049.